<?xml version="1.0" encoding="UTF-8"?>
<p id="p0360">These cytokine-licensed MSCs could be more effective in the suppression of hyperactive immune response and promotion of tissue repair, because it is known that cytokine-licensed MSCs were effective in preventing lipopolysaccharide (LPS)-induced acute lung damage 
 <xref rid="b0670" ref-type="bibr">[134]</xref>. So, several clinical trials are being carried out for evaluating the effectiveness of MSCs against COVID-19.
</p>
